Cipla Medpro South Africa announced that the company has signed a tri-party term sheet with Dr Falk GmbH and Orphan SA Pharmaceuticals (Pty) Ltd. In terms thereof an exclusive partnership is formed between Dr Falk and Cipla wherein the portfolio of Dr Falk’s previous local partner, Orphan SA Pharmaceuticals, will be taken over and commercialised by Cipla.
Paul Miller, CEO of Cipla South Africa, stated that out of the top 10 pharmaceutical companies in South Africa, Cipla is the fastest growing and currently positioned in the top 3 pharmaceutical companies in the country. “This acquisition speaks to the company’s ambition to continue to build on this growth trajectory through strategic alliances and we remain open to pursue similar deals in future.”
The deal includes a portfolio of 11 prescription products, which consist of a mixture of registered and pipeline products. The products fall within the Gastrointestinal category and are indicated to treat inflammatory bowel disease, including Crohn’s disease and ulcerative colitis, and primary biliary cirrhosis, amongst others. Moreover, the agreement prompts transfer of a speciality medical device from Orphan to Cipla, which would add value in diagnosing peptic ulcers.
“The move is in line with our new strategy to increase our focus and efforts to advancing healthcare for all South Africans. We will be implementing an intensive approach to grow our portfolio of quality and affordable pharmaceutical solutions in more therapeutic areas. These are very exciting additions to our current portfolio and we anticipate that the new products will contribute greatly to our top-line and growth aspirations,” concludes Miller.